- Home
- KROS vs GMTL Comparison
KROS vs GMTL Comparison
Compare KROS & GMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$11.29
N/A
Current Price
$15.68
Company Overview
Basic Information| Metric | KROS | GMTL |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.3M | 582.1M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | KROS | GMTL |
|---|---|---|
| Price | $11.29 | $15.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $21.86 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 321.2K | 201.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.79 | $12.75 |
| 52 Week High | $22.55 | $22.21 |
Technical Indicators
Market Signals| Indicator | KROS | GMTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 44.77 |
| Support Level | $10.47 | $12.75 |
| Resistance Level | $12.43 | $21.27 |
| Average True Range (ATR) | 0.68 | 1.51 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 59.09 | 54.94 |
Price Performance
Historical Comparison KROS
GMTL
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.